Different Prognostic Role of EGFR Mutation According to the IASLC Histologic Grade in Patients with Resected Early-Stage Lung Adenocarcinoma

• DOI: 10.2139/ssrn.4277225
• Publication Date: 2022-12-06T05:04:05Z
• Authors: Tae Hee Hong; Soohyun Hwang; Yoon-La Choi; Genehee Lee; Sehhoon Park; Myung-Ju Ahn; Yoonseo Lee; Yeong Jeong Jeon; Junghee Lee; Sumin Shin; Seong Yong Park; Jong Ho Cho; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Juhee Cho; Hong Kwan Kim
• Keywords: 0301 basic medicine; Lung Neoplasms; Adenocarcinoma of Lung; Adenocarcinoma; Prognosis; ErbB Receptors; 03 medical and health sciences; 0302 clinical medicine; Mutation; Humans; Neoplasm Staging; Retrospective Studies

Objective(s): In patients with resected early-stage lung adenocarcinoma, the prognostic role of EGFR mutation remains controversial. Histologic pattern is an important determinant prognosis, but most studies did not consider interaction between and accompanying histology.Methods: 3,297 stage I to IIA (8th) adenocarcinoma who had prospective tests January 2014 December 2019 at Samsung Medical Center, Seoul, Korea were included. Recurrence-free survival (RFS) was compared by status (EGFR-M+ vs. EGFR-WT) 2020 IASLC histologic grade (G1, low-grade; G2, intermediate-grade; G3, high-grade). Cox proportional hazards models used estimate adjusted HRs 95% CIs.Results: There a significantly lower proportion G3 tumors in EGFR-M+ group (16% 33%, p<0.001). During median follow-up 41.4 months, 376 experienced recurrence. After adjusting for grade, aHR recurrence comparing EGFR-WT 1.30 (95% CI: 1.04–1.62, p = 0.022). The 5-year RFS than among (58.4% 71.5%, < 0.001) G1 G2 patients.Conclusions: value differed according standard adenocarcinoma. These results would be useful developing new staging system identifying subset IA, IB, may require more aggressive strategies currently recommended.